Importance of five membered heterocyclic compounds in treatment of chronic myeloid leukemia by targeting various pathways
This review explores the chemical diversity, molecular interactions, and therapeutic potential of five-membered heterocyclic compounds in chronic myeloid leukemia (CML).
This review examines the role of five-membered heterocyclic compounds in chronic myeloid leukemia (CML) therapy, highlighting their structural diversity, favorable pharmacokinetics, and interactions with BCR::ABL1 and key signaling pathways such as PI3K/Akt, MAPK, and JAK/STAT. It underscores the potential of these scaffolds to overcome resistance to current tyrosine kinase inhibitors and to improve long‑term patient outcomes.
Chronic myeloid leukemia remains challenging due to drug resistance and adverse effects of current therapies. By targeting BCR::ABL1 and associated pathways, five‑membered heterocyclic compounds may offer more effective and less toxic treatment options, enhancing patient survival and quality of life.
Evidence level: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Related signals
- Treatment of chronic myeloid leukemia chronic phase patients in third-line setting and beyond: recommendations from a Belgian expert panel in 2025
- Chronic myeloid leukemia: Current guidelines for diagnosis and management
- Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment‑free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co‑primary endpoint
- Information about Project 4: Chronic myeloid leukemia (CML)
- Prevalence and characterization of germline RAS pathway variants in children with chronic myeloid leukemia